Daiichi Sankyo, Merck ink $22-billion cancer drug deal, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

Daiichi rose as much as 18 per cent on Friday, the biggest intraday jump since 2005, after Merck agreed to pay $4 billion upfront and as much as $22 billion to develop and market three cancer drug candidates. One them is them slated to seek US approval by March 2024, the company said in a statement. Daiichi will retain the rights for these drugs in Japan., Daiichi rose as much as 18 per cent on Friday, the biggest intraday jump since 2005, after Merck agreed to pay $4 billion upfront and as much as $22 billion to develop and market three cancer drug candidates. One them is them slated to seek US approval by March 2024, the company said in a statement. Daiichi will retain the rights for these drugs in Japan., , Read More